Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Isis Earns Ortho-McNeil Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Isis Earns Ortho-McNeil Milestone

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Isis Pharmaceuticals, Inc. earned $5 million from Ortho-McNeil, Inc. (OMI), a Johnson & Johnson company, for achieving the first development milestone of initializing the Phase I trial of ISIS 325568.

The collaboration, announced in September 2007, includes the licensing of two second-generation antisense drugs, ISIS 325568 and ISIS 377131, for the treatment of metabolic disease. ISIS 325568 was designed to selectively inhibit the production of glucagon receptor and has demonstrated improved glucose control in animal models of Type 2 diabetes.

“We are pleased to have achieved this milestone so early in our collaboration with Ortho-McNeil, Inc.,” said Jeffrey Jonas, M.D., executive vice president, Isis Pharmaceuticals. “OMI will be providing all funding for this study, while Isis will be managing the study through to completion before handing all additional development responsibilities over to our partner.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters